Zura Bio Ltd (94E.SG)
| Previous Close | 4.3200 |
| Open | 4.2200 |
| Bid | 4.3200 x N/A |
| Ask | 4.4600 x N/A |
| Day's Range | 4.2200 - 4.2200 |
| 52 Week Range | 1.8700 - 11.3000 |
| Volume | |
| Avg. Volume | 5 |
| Market Cap | N/A |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Business Wire
Zura Bio Reports First Quarter 2024 Financial Results and Recent Business Highlights
HENDERSON, Nev., May 09, 2024--Zura Bio Limited (Nasdaq: ZURA) ("Zura Bio"), a clinical stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today reported its first quarter 2024 financial results, and recent business highlights.
- Business Wire
Zura Bio Announces Oversubscribed $112.5 Million Private Placement
HENDERSON, Nev., April 18, 2024--Zura Bio Limited (Nasdaq: ZURA) ("Zura Bio"), a clinical stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today announced that it has entered into subscription agreements for a private placement that is expected to result in gross proceeds of approximately $112.5 million, before deducting placement agent fees and offering expenses (the "Private Placement").
- Business Wire
Zura Bio Announces Robert Lisicki as CEO and Director
HENDERSON, Nev., April 08, 2024--Zura Bio Limited (Nasdaq: ZURA) ("Zura Bio") a clinical-stage immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today announced that Robert Lisicki has assumed the role of Chief Executive Officer and a Director of the Board at Zura Bio. The Company previously announced Mr. Lisicki's appointment and the commencement of a seamless transition process with Founding CEO, Dr. Someit Sidhu. This transition marks a key
